# US 2019/0316097 A1 · Variant forms of urate oxidase and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316097 A1
- Document ID: US20190316097A1
- Status: Published application
- Kind: A1
- Application number: 16/202,743
- Filed: 2018-11-28
- Published: 2019-10-17
- Earliest claimed: 2005-04-11
- Assignees: Horizon Pharma Rheumatology LLC
- Applicants: Horizon Pharma Rheumatology LLC
- Inventors: Jacob Hartman; Simona Mendelovitz
- Web page: https://patentgrep.com/patent/US20190316097A1

## CPC

- C12N 9/0048: {Uricase (1.7.3.3)}
- A61K 38/44: Oxidoreductases (1)
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 13/12: of the kidneys
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/0046: {with oxygen as acceptor (1.7.3)}
- C12Y 107/03003: Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

## Claims

### Claim at position 1

1-37. (canceled)

### Claim 38

A method of reducing elevated uric acid levels in a subject in need thereof, comprising intravenously administering a pharmaceutical composition comprising:
a conjugate comprising a tetrameric uricase and polyethylene glycol (PEG), wherein the uricase comprises the amino acid sequence of SEQ ID NO: 8; and
phosphate buffered saline (PBS).

### Claim 39 (depends on 38)

The method of claim 38, wherein the PEG is monomethoxyPEG (mPEG).

### Claim 40 (depends on 39)

The method of claim 39, wherein the mPEG has a molecular weight between 5 kDa and 20 kDa.

### Claim 41 (depends on 40)

The method of claim 40, wherein the mPEG has a molecular weight of about 10 kDa.

### Claim 42 (depends on 41)

The method of claim 41, wherein the mPEG is covalently attached to a lysine residue of the uricase.

### Claim 43 (depends on 41)

The method of claim 41, wherein the conjugate comprises about 2-12 mPEG molecules per uricase monomer.

### Claim 44 (depends on 43)

The method of claim 43, wherein the pharmaceutical composition comprises 8 mg of the uricase.

### Claim 45 (depends on 38)

The method of claim 38, wherein the pharmaceutical composition comprises 8 mg of the uricase per mL of solution.

### Claim 46 (depends on 45)

The method of claim 45, wherein the pharmaceutical composition is diluted into 250 mL of saline solution for administration.

### Claim 47 (depends on 38)

The method of claim 38, wherein the pharmaceutical composition is administered at a dosage of 8 mg of the uricase.

### Claim 48 (depends on 38)

The method of claim 38, wherein the pharmaceutical composition is administered at a dosage of 8 mg of the uricase every two weeks.

### Claim 49 (depends on 38)

The method of claim 38, wherein the pharmaceutical composition is administered over a 120-minute period.

### Claim 50 (depends on 49)

The method of claim 49, wherein the uric acid level is reduced in the plasma of the subject.

### Claim 51 (depends on 50)

The method of claim 50, wherein the plasma uric acid level is lowered to 6.0 mg/dl or less.

### Claim 52 (depends on 50)

The method of claim 50, wherein the subject has a plasma uric acid level of 6.0 mg/dl or less for at least 80% of a treatment period.

### Claim 53 (depends on 48)

The method of claim 48, wherein the subject receives an antihistamine or a corticosteroid prior to the administration of the conjugate.

### Claim 54 (depends on 48)

The method of claim 48, wherein the subject receives acetaminophen prior to the administration of the conjugate.

### Claim 55 (depends on 48)

The method of claim 48, wherein the subject receives a nonsteroidal anti-inflammatory drug (NSAID) prior to the administration of the conjugate.

### Claim 56 (depends on 48)

The method of claim 48, wherein the subject is an adult subject.

### Claim 57 (depends on 48)

The method of claim 48, wherein the subject is suffering from gout.

### Claim 58 (depends on 48)

The method of claim 48, wherein the subject is suffering from gout that is refractory to conventional therapy.
